Results For "0"

Getting started with in-house development: how does it work? Blog Post

Introducing our three-part blog series on getting started with in-house development. In this series, we’re detailing some key aspects of how you can create and deploy your own mobile apps,…

How to Demonstrate Virtual Bioequivalence for Complex Dermal Generic Drugs Blog Post

このウェビナーでは、サターラが PBPK Simcyp Simulator を拡張し、広範な皮膚モデルである MPML MechDermA（多相、多次元皮膚吸収モデル）を組み込んだ方法について説明します。

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110 Blog Post

Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development Blog Post

Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic neuralgia & fibromyalgia.

Patient Engagement and Patient Centricity Series Part II: Types of Patient Advocates Blog Post

Nirpal Virdee, Synchrogenix’s Global Head of Transparency and Disclosure recently sat down with Trishna Bharadia, award-winning health advocate and patient engagement champion, for a discussion around patient engagement and patient…

ICER’s Unsupported Drug Price Increase Report: An Analysis Blog Post

We analyze the drug-price watchdog, ICER’s (Institute for Clinical and Economic Review) “Report on Unsupported Price Increases.”

Health Canada PRCI Guiding Principles and Observations Blog Post

Health Canada released guidance on 2019年3月12日 pertaining to its Public Release of Clinical Information (PRCI) initiative. Health Canada’s objective with this initiative is to make anonymized clinical information…

Common Questions about Define-XML and the Stylesheet Blog Post

In this blog, we answer common questions about Define-XML and the Stylesheet, including all you need to know for study submission and what version to use.

Innovative Solutions for Fast-Tracking Drugs for Rare Diseases Blog Post

This webinar discussed which pharmaceutical payer strategies work and which don’t in our rapidly changing regulatory and reimbursement world.

Advanced Analytics Using RWD Mitigates Risks in AD Drug Development & Reimbursement Blog Post

This webinar explained how advanced analytics using real-world data can mitigate challenges in Alzheimer’s disease drug approval, reimbursement and utilization.